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Presence of antibody to adenylate cyclase toxin (ACT) has been noted following Bordetella pertussis infection.
Because ACT is not presently in any acellular pertussis vaccines, it has been considered as a possible antigen
to use in B. pertussis diagnostic enzyme-linked immunosorbent assay (ELISA) studies. We determined antibody
to B. pertussis ACT by ELISA and Western blot tests in serum samples obtained from unvaccinated children,
from children vaccinated with several diphtheria and tetanus toxoid vaccines (DTP vaccines), from children
vaccinated with vaccines containing acellular pertussis components in combination with diphtheria and tetanus
toxoids (DTaP vaccines), and from children and adults with pertussis. Primary infections with either B. pertussis
or Bordetella parapertussis stimulated a vigorous antibody response to ACT. In contrast, patients in whom
DTP and DTaP vaccines failed had minimal ACT antibody responses. The lack of a significant ACT antibody
response in children in whom the vaccine failed is of interest but would seem to preclude the use of ACT in
diagnostic tests.
Whooping cough (pertussis) is an infectious disease
found in both children and adults and caused by the
gram-negative bacterium Bordetella pertussis [1, 2]. B.
pertussis has a number of virulence factors, including
fimbriae, pertactin (PRN), pertussis toxin (PT), fila-
mentous hemagglutinin (FHA), lipooligosaccharide,
and adenylate cyclase toxin (ACT). ACT is an impor-
tant virulence factor of B. pertussis which disrupts host
cyclic 3′,5′-adenosine monophosphate (cAMP) metab-
olism [1–4]. ACT enters a variety of mammalian cells
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and can inhibit the microbicidal cytotoxic function of
neutrophils, monocytes, and natural killer cells. Its con-
tribution to clinical pertussis may be through impair-
ment of host defenses or through a direct effect on the
respiratory mucosa.
The use of B. pertussis ACT for diagnosis of pertussis
was described by Confer and Eaton [5]. Nasopharyn-
geal swab specimens carrying as few as 100 B. pertussis
cfu induced detectable levels of cAMP. Previous im-
munoblotting studies looked for antibodies to ACT in
serum samples obtained from infants, children, and
adults [6, 7]. Farfel et al. [7] found ACT antibody in
the serum samples of the following subject groups: 15
patients with pertussis, 4 neonates, 4 previously vac-
cinated children between 2 and 3 years old, and 4 adults
who had been vaccinated as children. They did not
detect ACT antibody in the serum samples of 4 un-
vaccinated infants between 4 and 5 months old. Arci-
niega et al. [6] found ACT antibody in the serum sam-
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ples of 5 patients with pertussis but not in the serum samples
of 6 infants who were immunized with vaccine containing
whole cell pertussis in combination with diphtheria and tetanus
toxoids (DTP vaccine).
In the 1990s, several large vaccine efficacy trials were per-
formed for the evaluation of vaccines with acellular pertussis
components in combination with diphtheria and tetanus tox-
oids (DTaP vaccines) [1]. In these trials, diagnosis was estab-
lished in many instances by the demonstration of an increase
in antibody titer in response to PT and other B. pertussis an-
tigens (FHA, PRN, and fimbriae). Because1 of these antigens
was contained in each of the various DTaP vaccines evaluated,
there was concern that this would result in a disproportionate
identification of cases among patients in the control group
(compared with patients who were vaccinated) and would
therefore inflate the reported efficacy of the vaccine.
In consideration of the factors above, it would seem ideal
to use an antigen that is Bordetella species–specific and not
included in a DTaP vaccine for serologic diagnosis. B. pertussis
ACT has been cloned in Escherichia coli by recombinant tech-
nology and can therefore be produced in large amounts [3, 4].
In contrast to immunoblotting, ELISA allows the determination
of specific quantitative ACT antibody values. To gain a broader
understanding of the human immune response to B. pertussis
ACT, we examined antibodies to ACT by ELISA and immu-
noblotting in serum samples obtained from DTP or DTaP vac-
cine recipients; unvaccinated children with and without per-
tussis; adults with pertussis; DTP or DTaP recipients who
subsequently had pertussis; and unvaccinated children with B.
parapertussis illnesses.
MATERIALS AND METHODS
Serum specimens. Serum samples were obtained from chil-
dren who were subjects in 4 vaccine efficacy studies and from
German children and adults with pertussis [8–13]. Informed
consent was obtained from study subjects or their parents or
guardians, and the human experimentation guidelines of the
US Department of Health and Human Services and those of
the specific trial sites in Sweden, Italy, and Germany were fol-
lowed. Serum samples were specifically collected to determine
antibodies to B. pertussis antigens.
Antigen and reagents. B. pertussis ACT that had been
produced in E. coli was used (kindly provided by Dr. J. Coote,
University of Glasgow) [3]. The possibility of cross-reactions
in the serum samples to residual E. coli antigens was assessed
in a pilot study. The serum samples were incubated with the
parent E. coli strain (∼108 cells/mL) at 37C overnight; bacteria
were then removed by centrifugation. ELISA was performed
on the supernatants for ACT antibody. The ELISA results ob-
tained from samples that underwent this treatment were com-
pared with results obtained from samples that were not in-
cubated with the parent E. coli strain, and there was no
significant difference between the 2 groups. To our knowledge,
there is no reference serum for ACT antibody available, and
therefore, for standardization, a freeze-dried preparation of a
human serum sample with antibodies to other B. pertussis an-
tigens, provided by the National Institute for Biological Stan-
dards and Control, United Kingdom (NIBSC, code 89/530),
was used as an in-house reference in this study. This preparation
has been assigned to have antibody to ACT at a concentration
of 100 U/mL. All other reagents used were analytical grade
unless otherwise stated.
Determination of titers of ACT antibodies by ELISA.
ELISA was used to determine titers of IgG ACT antibodies in
each of the serum samples. In brief, wells of microtiter plates
were coated with 100 mL of ACT at a concentration of 2 mg/
mL in carbonate coating buffer (pH 9.6) for 18 h at room
temperature. After blocking and washing 3 times with PBS/
Tween/10% fetal calf serum (PBSTF), 2-fold dilutions of the
reference serum sample and serum samples to be tested in
PBSTF were performed on the plate and incubated for 2 h at
room temperature. The negative control wells were treated in
a similar fashion but did not contain serum samples. After the
incubation with anti-human peroxidase conjugate (IgG; Sigma)
in PBSTF for 2 h at room temperature, the wells were washed,
and 100 mL of substrate solution containing hydrogen peroxide-
tetramethylbenzidine was added to all of the wells. Color was
allowed to develop for 15 min at room temperature, and 50
mL of sulfuric acid at a concentration of 1 mol/L was added to
stop the reaction. The plates were then read at an optical density
of 450 nm on an Anthos plate reader (Anthos Labtec Instru-
ments, Austria).
The cutoff point for each individual assay was calculated as
the mean optical density for the negative control wells plus 2
SDs. On the basis of 92 assays, the detection limit for this assay
was established as 2 ELISA units per milliliter (EU/mL) of the
standard serum 89/530. Antibody levels in samples giving es-
timates below the detection limit were regarded as undetectable.
The ELISA units were calculated for each of the serum samples
against the reference serum 89/530 according to the principles
of multiple parallel line bioassay, by comparison of transformed
assay response to log concentration with use of 4 dilutions
in the linear range. Assay precision was assessed by 3 additional
tests that were performed on 3 different days on 5 serum sam-
ples. The coefficient of variation was 3.41%. In all cases, an
analysis of variance gave an assessment of linearity and par-
allelism, which are required as a measure of the statistical va-
lidity of the analysis. Ninety-five percent fiducial limits were
calculated, and Student’s t test was used for comparison be-
tween groups; was regarded as statistically significant.P ! .05
Immunoblotting. The 200-kDa ACT antigen (6.4 mg) and
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Table 1. Geometric mean titers (GMTs) of antibody to adenylate cyclase toxin (ACT) in serum samples from children who
received 2–4 doses of diphtheria, tetanus toxoid, and acellular pertussis (DTP), acellular pertussis components in combination
with diphtheria and tetanus toxoids (DTaP), or diphtheria-tetanus (DT) vaccines.
Vaccine, manufacturer










DT, German, Swedish None 7 2–3 13 18 (11–30)
DTP, Connaught, US Multiple 7 3 10 25 (18–37)
DTP, Lederle, US Multiple 17 4 20 28 (19–40)
DTP, Evans, UK Multiple 7 3 5 43 (20–93)
DTaP, SKB PT, FHA 7 3 9 30 (20–45)
DTaP, Chiron PT, FHA, PRN 7 3 10 21 (14–32)
DTaP, SKB PT, FHA, PRN 7 3 5 15 (7–35)
DTaP, Lederle/Takeda PT, FHA, PRN, Fim-2 21 4 10 15 (10–22)
DTaP, Connaught, Canada PT, FHA, PRN, Fim-2, Fim-3 7 3 10 24 (17–35)
NOTE. EU, ELISA units; FHA, filamentous hemagglutinin; Fim-2, fimbriae type 2; Fim-3, finbriae type 3; PT, pertussis toxin; PRN, pertactin.
a Median age at the time that serum samples were obtained.
a marker (molecular weight, 4–250 kDa) were subjected to 8%
acrylamide trisglycine gel (Invitrogen) in the presence of SDS-
PAGE and then transferred to nitrocellulose by electrophoresis.
After washing and blocking, the individual strips were then
reacted with the reference serum or test serum samples (1:500)
overnight at room temperature. The strips were washed and
then incubated for 2 h with an anti-human peroxidase (IgG)
conjugate. The strips were then stained with diaminobenzidine
tablets as a peroxidase substrate. The blots were scanned with
a scanner and analyzed using Adobe Photoshop software, ver-
sion 4. The Phoretix 1D quantifier version 5.00 was used to
detect the intensity of the bands at 200 kDa for the test and
reference samples. For standardization, the ratio of the intensity
of a test sample divided by the intensity of a reference sample
from the same blot was used to express the results. A ratio
1.0 was regarded as positive.
RESULTS
The ACT ELISA postimmunization geometric mean titers
(GMT) of antibody in the serum samples of healthy infants
who received diphtheria-tetanus (DT), DTP, or DTaP vaccines
are presented in table 1. Thirteen infants received 2 or 3 doses
of German- or Swedish-licensed DT vaccines; 35 infants re-
ceived 3 or 4 doses of licensed DTP vaccines (10 received US-
licensed Connaught vaccine, 20 received US-licensed Lederle
vaccine, and 5 received UK-licensed Evans Medical vaccine);
and 44 received 3 or 4 doses of investigational DTaP vaccines.
Nine infants received a 2-component (PT and FHA) vaccine
manufactured by SmithKline Beecham; 10 infants received a
3-component (PT, FHA, PRN) Chiron vaccine; 5 infants re-
ceived a 3-component (PT, FHA, PRN) vaccine manufactured
by SmithKline Beecham; 10 infants received a 4-component
(PT, FHA, PRN, fimbriae type 2) Lederle/Takeda vaccine; and
10 infants received a 5-component (PT, FHA, PRN, fimbriae
type 2, and fimbriae type 3) Connaught-Canada vaccine.
As can be seen, all serum samples from these infants and
vaccinated children had low values of antibody to ACT (table
1) in comparison with the values for serum samples obtained
from unvaccinated children with B. pertussis or B. parapertussis
infections (table 2). The mean values for the serum samples of
the DT-, DTP-, and DTaP-recipient subgroups were not sta-
tistically different. However, 2 of 5 recipients of the Evans DTP
vaccine and 3 of 20 recipients of the Lederle DTP vaccine had
ELISA serum values 13-fold greater than the mean serum value
(18 EU/mL) for DT recipients. These values were 68 and 97
EU/mL, for the recipients of the Evans DP vaccine, and 118,
106, and 73 EU/mL, for the recipients of the Lederle DTP
vaccine.
The ELISA values of antibody to ACT in convalescent-phase
serum samples from previously vaccinated or unvaccinated
children with pertussis due to B. pertussis or B. parapertussis
infections are presented in table 2. In unvaccinated children,
the serum GMTs after pertussis due to B. pertussis or B. par-
apertussis infections were elevated: 872 EU/mL and 512 EU/
mL, respectively (48- and 28-fold greater than the GMTs in
unvaccinated infants). Only 1 of the subjects, an 8-month-old
infant, had a low titer in the convalescent-phase blood sample
(titer, 16 EU/mL). In contrast, the GMTs in convalescent-phase
serum samples obtained from subjects in whom vaccination
had failed were only slightly elevated. The GMT in the serum
samples obtained from subjects for whom DTP () vaccine failed
was 92 EU/mL, and it was 49 EU/mL in the serum samples of
subjects for whom DTaP (Lederle/Takeda) vaccine failed (5-
and 3-fold greater than the GMT in serum samples obtained
from unvaccinated infants).
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Table 2. Geometric mean titers (GMTs) of antibody to adenylate cyclase toxin (ACT) in convalescent-phase
serum samples obtained from previously vaccinated or unvaccinated children with pertussis due to Bordetella
pertussis or Bordetella parapertussis infections.
Patient group
No. of




Unvaccinated with B. pertussis infection 20 8 years (8–16 years) 872 (507–1500)
Unvaccinated with B. parapertussis infection 4 21 months (14–8 years) 512 (186–1412)
Experienced DTP (Lederle) vaccine failure 5 16 months (13–41 months) 92 (49–173)
Experienced DTaP (Lederle/Takeda) vaccine failure 10 25 months (15–36 months) 49 (27–86)
NOTE. DTaP, acellular pertussis components in combination with diphtheria and tetanus toxoids; DTP, diphtheria, tetanus
toxoid, and acellular pertussis; EU, ELISA units.
Acute- and convalescent-phase serum specimens were avail-
able from the 5 children who experienced DTP vaccine failure.
No increase in titer occurred; the acute-phase GMT and the
convalescent-phase GMT were both 92 EU/mL. As noted in
the findings of vaccine efficacy trials conducted by members
of our group [8] and others [9, 13], the clinical illnesses of
children who experienced DTP and DTaP vaccine failure were,
on average, less severe than the illnesses of unvaccinated chil-
dren. When illnesses in the 2 vaccine-failure groups are com-
pared, illnesses among the patients who received DTaP vaccine
seem less typical of classic pertussis than do illnesses among
those who received DTP vaccine. All 5 patients for whom DTP
vaccine failed had some combination of paroxysmal cough,
whoop, or posttussive vomiting, whereas only 6 of 10 patients
for whom DTaP vaccine failed had similar clinical findings.
Immunoblotting was performed on the serum samples ob-
tained from the children in the German vaccine trial [8]. Of
the 24 subjects with pertussis due to B. pertussis or B. para-
pertussis infection, only 2 subjects with B. pertussis infections
did not have immunoblotting results positive for ACT antibody
(table 2). In contrast, only 1 of the 20 patients who received
the Lederle DTP vaccine had a positive immunoblotting result,
and none of the 10 Lederle/Takeda DTaP vaccine recipients had
immunoblotting results that were positive for ACT antibody
(table 1). Of those patients for whom vaccination failed (5 of
whom received DTP vaccine and 10 of whom received DTaP
vaccine), only 3 recipients of DTaP vaccine had weakly positive
immunoblotting results for ACT antibody (table 2).
Over a period of ∼2.5 years, we obtained acute-phase and
follow-up serum specimens from 11 adults with confirmed B.
pertussis infections [11]. Using these serum samples, over time
we have performed ELISAs to determine antibody values to
PT, FHA, PRN, and fimbriae, and we have now determined
ACT ELISA antibody values. The ACT GMT increased between
3-fold and 4-fold, and this titer persisted for the 28 months of
follow-up. This pattern is dissimilar to that found for PT, but
it is somewhat similar to that found for FHA and PRN.
DISCUSSION
ACT is an important toxin that contributes to disease caused
by B. pertussis and B. parapertussis [1–4]. Because the efficacy
of the various DTaP vaccines is not optimal, ACT has been a
candidate for inclusion in more-complete vaccines. However,
at the present time, ACT has not been included as an antigen
in any of the available DTaP products. The study by Farfel et
al. [7] suggested that DTP vaccines had elicited ACT antibody
responses. However, because the serum samples studied were
obtained from adults and children between 2 and 3 years old
who were vaccinated in infancy, it is likely that the ACT an-
tibodies found were attributable to previously unrecognized
Bordetella infections [1, 14, 15].
In this investigation, all serum samples obtained from 10
healthy infants (DT recipients) had low values of antibody to
ACT, as measured by ELISA. Similarly, the postimmunization
GMTs of all vaccine groups (i.e., recipients of the DTP vaccine
and the DTaP vaccine) were also low (table 1). However, of all
vaccine recipients, only 2 recipients of the Evans DTP vaccine
and 3 recipients of the Lederle DTP vaccine had modestly el-
evated ACT antibody titers (68 and 97 EU/mL and 118, 106,
and 73 EU/mL, respectively). Of the 3 Lederle DTP recipients
with elevated titers, none had positive Western blot results.
The low titers of ACT antibody in the serum samples of the
13 unvaccinated infants (as well as in the serum samples of
almost all of the healthy patients who received vaccine) are of
interest. These values could be the result of residual antibodies,
acquired transplacentally from the mother. However, this seems
unlikely, because there was no significant difference in the
GMTs of the groups from whom serum samples were obtained
during the second year of life, compared with those of the
groups from whom serum samples were obtained at 7 months
of age. Further, !5% of infants would be expected to have a
measurable titer of residual transplacentally acquired antibodies
at 7 months of age [16].
There are 2 more-likely possible explanations for the ACT
antibody values present in the serum samples obtained from
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healthy infants. B. pertussis ACT is a member of the repeat
toxin family of cytotoxins, which are also produced by E. coli
and other gram-negative bacteria [17]. Because there is a sim-
ilarity between the amino acid sequences of the c-terminal do-
main of ACT and those of the hemolysins of E. coli and other
gram-negative bacteria, it is possible that the low titers we noted
are attributable to cross-reacting antibodies generated in re-
sponse to E. coli or other organisms in the normal bowel flora
[18, 19]. In support of this hypothesis, Arciniega et al. [18]
studied serum samples obtained from neonates and their moth-
ers and noted that the samples contained antibodies to ACT
and to the a-hemolysin of E. coli.
Another possibility relates to the production of ACT during
human metabolism. Specifically, ACT catalyzes the synthesis of
cAMP in eukaryotic cells, which acts as a messenger in the
action of many hormones [20, 21]. It is possible that ACT is
released from the cell in certain circumstances, such as at cell
death. It is not known, however, if autoantibodies to autologous
ACT would cross-react significantly with B. pertussis ACT.
However, Goyard et al. [21] found that eukaryotic ACT con-
tained an epitope closely related to that specified by a conserved
B. pertussis sequence.
The high titers in convalescent-phase serum samples ob-
tained from patients with pertussis due to B. pertussis or B.
parapertussis infection suggest the possibility of using ACT an-
tigen detection with ELISA for the diagnosis of pertussis. How-
ever, it is apparent that results obtained using ACT antigen are
inferior to those obtained using PT antigen. Antibody to ACT
is less specific than antibody to PT, and, because ACT is com-
mon to Bordetella species, detection of antibody to ACT offers
no advantage over detection of FHA or PRN antigens. Of par-
ticular interest is the lack of a significant ACT antibody response
in children for whom the DTP or DTaP vaccines failed. This
induced tolerance is intriguing and may be due to the phe-
nomenon called “original antigenic sin” [22]. In this phenom-
enon, a child responds at initial exposure to all presented epi-
topes of the infecting agent or vaccine. With repeated exposure
when older, the child responds preferentially to those epitopes
shared with the original infecting agent or vaccine and can be
expected to have responses to new epitopes of the infecting
agent that are less marked than normal. Because both vaccines
contained multiple antigens (i.e., PT, FHA, PRN, and fimbriae),
the patients who had been vaccinated responded to the antigens
that they had been primed with and did not respond to the
new antigen (i.e., ACT) associated with infection. It is of interest
that the GMT was higher among the patients for whom DTP
vaccination failed than it was among the patients for whom
DTaP vaccination failed. This suggests the possibility that small
amounts of ACT were present in the DTP vaccine. This pos-
sibility is supported by the finding of slightly elevated ACT
postvaccination titers in 5 of 25 recipients of the DTP vaccine.
The data concerning antibody decay after infection in adults
is also revealing. The pattern of decay of antibody to PT is
different from that of antibody to ACT, FHA, PRN, and fim-
briae [23]. The persistence of antibodies to the latter 4 antigens
may result from continued stimulation by cross-reacting an-
tigens from other infectious agents [23, 24]. Antibody to PT
decreases more acutely because this antigen is B. pertussis
exclusive.
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